Distribution of [11C]-JNJ-42491293 in the marmoset brain: a positron emission tomography study

[1]  P. Conn,et al.  Metabotropic Glutamate Receptors As Emerging Targets for the Treatment of Schizophrenia , 2022, Molecular Pharmacology.

[2]  P. Calabresi,et al.  Striatal glutamatergic hyperactivity in Parkinson's disease , 2022, Neurobiology of Disease.

[3]  Lei Chen,et al.  Metabolomics Provides Novel Insights into Epilepsy Diagnosis and Treatment: A Review , 2022, Neurochemical Research.

[4]  Christine L. Tardif,et al.  Co-registration of Imaging Modalities (MRI, CT and PET) to Perform Frameless Stereotaxic Robotic Injections in the Common Marmoset , 2021, Neuroscience.

[5]  J. Diamond,et al.  Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels , 2021, Pharmacological Reviews.

[6]  M. Ondrechen,et al.  Design, synthesis, and characterization of [18F]mG2P026 as a high contrast PET imaging ligand for metabotropic glutamate receptor 2 , 2021, bioRxiv.

[7]  M. Ondrechen,et al.  Synthesis and characterization of 5-(2-fluoro-4-[11C]methoxyphenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine-7-carboxamide as a PET imaging ligand for metabotropic glutamate receptor 2 , 2021, bioRxiv.

[8]  G. El Fakhri,et al.  Synthesis and Characterization of [18F]JNJ-46356479 as the First 18F-Labeled PET Imaging Ligand for Metabotropic Glutamate Receptor 2 , 2021, Molecular Imaging and Biology.

[9]  Stephen Nuara,et al.  Effect of the mGlu2 positive allosteric modulator CBiPES on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset , 2021, Journal of Neural Transmission.

[10]  K. Gregory,et al.  International Union of Basic and Clinical Pharmacology. CXI. Pharmacology, Signaling, and Physiology of Metabotropic Glutamate Receptors , 2020, Pharmacological Reviews.

[11]  Steven H. Liang,et al.  Synthesis and preliminary studies of 11C-labeled tetrahydro-1,7-naphthyridine-2-carboxamides for PET imaging of metabotropic glutamate receptor 2 , 2020, Theranostics.

[12]  M. Panisset,et al.  Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset. , 2020, European journal of pharmacology.

[13]  A. Parent,et al.  The highly selective mGlu2 receptor positive allosteric modulator LY‐487,379 alleviates l‐DOPA‐induced dyskinesia in the 6‐OHDA‐lesioned rat model of Parkinson's disease , 2020, The European journal of neuroscience.

[14]  G. Dienel.  Brain Glucose Metabolism: Integration of Energetics with Function. , 2019, Physiological reviews.

[15]  Andrew S. Felts,et al.  Differential Pharmacology and Binding of mGlu2 Receptor Allosteric Modulators , 2018, Molecular Pharmacology.

[16]  C. Brittain,et al.  Evaluation of single and multiple doses of a novel mGlu2 agonist, a potential antipsychotic therapy, in healthy subjects , 2017, British journal of clinical pharmacology.

[17]  Arnau Cordomí,et al.  Molecular Switches of Allosteric Modulation of the Metabotropic Glutamate 2 Receptor. , 2017, Structure.

[18]  Mark E. Schmidt,et al.  What We Observe In Vivo Is Not Always What We See In Vitro: Development and Validation of 11C-JNJ-42491293, A Novel Radioligand for mGluR2 , 2017, The Journal of Nuclear Medicine.

[19]  C. Bissantz,et al.  Pharmacological and molecular characterization of the positive allosteric modulators of metabotropic glutamate receptor 2 , 2016, Neuropharmacology.

[20]  Piotr Majka,et al.  Towards a comprehensive atlas of cortical connections in a primate brain: Mapping tracer injection studies of the common marmoset into a reference digital template , 2016, The Journal of comparative neurology.

[21]  Mark A. Smith,et al.  AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study , 2014, Schizophrenia Research.

[22]  Y. Shaham,et al.  The Novel Metabotropic Glutamate Receptor 2 Positive Allosteric Modulator, AZD8529, Decreases Nicotine Self-Administration and Relapse in Squirrel Monkeys , 2015, Biological Psychiatry.

[23]  Vikash K. Sinha,et al.  Pharmacokinetic and pharmacodynamic characterisation of JNJ-40411813, a positive allosteric modulator of mGluR2, in two randomised, double-blind phase-I studies , 2015, Journal of psychopharmacology.

[24]  María Lourdes Linares,et al.  Discovery of 3-cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4,3-a]pyridine (JNJ-42153605): a positive allosteric modulator of the metabotropic glutamate 2 receptor. , 2012, Journal of medicinal chemistry.

[25]  G. Bormans,et al.  Synthesis, evaluation, and radiolabeling of new potent positive allosteric modulators of the metabotropic glutamate receptor 2 as potential tracers for positron emission tomography imaging. , 2012, Journal of medicinal chemistry.

[26]  S. Mosolov,et al.  Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial , 2007, Nature Medicine.

[27]  C. Muhtz,et al.  Effects of a metabotropic glutamate2/3 receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results , 2005, Psychopharmacology.